Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRAX-050
- Development stage
- Preclinical
- Lead developer
- Praxis Precision Medicines
- Modality
- Small Molecules
01
Overview
PRAX-050 is an early-stage small molecule drug candidate being developed by Praxis Precision Medicines. It is intended for the treatment of movement disorders. While the company's portfolio frequently focuses on modulating ion channels and neurotransmitter receptors to treat central nervous system disorders, the specific biological target and mechanism of action for PRAX-050 have not yet been publicly disclosed. The program is currently in the early stages of development, following the company's more advanced candidates like ulixacaltamide.
Beyond the preview
Go deeper on PRAX-050.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRAX-050.